Kalinichev Mikhail both disposed of and received 306,765 Addex Therapeutics shares on 2026-09-02, while also disposed of and received 200,000 derivative securities. The transaction records show his holdings at 306,765 shares and 200,000 derivative securities after the awards, giving investors a precise view of reported ownership changes.
Key Highlights
- Kalinichev Mikhail held 200,000 Addex derivative securities after the transaction.
- The transactions occurred on 2 September 2026 under SEC codes D and A.
- Kalinichev Mikhail is identified as Addex Therapeutics’ head of translational science.
Kalinichev Mikhail was awarded 306,765 shares of Addex Therapeutics Ltd. and 200,000 derivative securities on 2 September 2026. The transactions also recorded dispositions of the same respective quantities, with post-transaction ownership listed at 306,765 shares and 200,000 derivative securities.
Addex Awards and Dispositions Recorded
Kalinichev Mikhail is identified as Addex Therapeutics Ltd.’s head of translational science. The share transactions used SEC transaction codes D for the dispositions and A for the awards. The records show a disposal of 306,765 Addex shares, followed by ownership of zero shares, and an award of 306,765 shares, followed by ownership of 306,765 shares. Derivative-security activity followed the same pattern: 200,000 were disposed of, 200,000 were awarded, and post-transaction ownership was listed at 200,000 derivative securities.
Reported Holdings After Awards
The reported post-transaction holdings were 306,765 Addex shares and 200,000 derivative securities. The transaction date for both classes was 2 September 2026.




Please wait processing your request...